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Regulatory guidelines for the registration of new chemical entities represent the cornerstone of the clinical development for new
medications. They usually extensively describe the various steps leading a pharmaceutical company, usually called the
Applicant, to seek for marketing authorization. These guidelines start from Phase I studies towards the final steps, including
Phase III pivotal trials. At this stage, regulatory agencies, in Europe the Committee for Human Medicinal Products (CHMP), at
the European Medicine Evaluation Agency (EMEA), will assess the risk/benefit ratio of a new chemical entity, taking into
account its efficacy and safety in a particular indication. In order to make sure that these regulatory guidelines do meet the
highest scientific level, it is of prime importance to facilitate interactions between members of the regulatory authorities,
academics scientists and representatives of the pharmaceutical industry. The Group for the Respect of Ethics and Excellence in
Science (GREES) is a not-for-profit organization, registered in Belgium, in 1985. It works by invitation only and is currently listed
as an "interested body" with EMEA. GREES has, for objective, to organize meetings with representatives of regulatory
authorities, academic scientists and experts from the pharmaceutical industry. It works on the basis of "ad hoc" sections,
activated at the request of regulatory authorities or pharmaceutical industry when scientific issues are raised, during the
preparation of guidelines for the registration of new chemical entities in a specific medical area. The objective of the GREES is
to prepare working documents, that will be submitted to regulatory authorities and, if deemed necessary, will serve as
preliminary working documents for National or European regulatory authorities. GREES participants work on a pro-bono basis
and no funding is provided to the GREES by the pharmaceutical industry. So all GREES members are fully independent and
GREES meetings do not generate competing interests. The outcomes of the GREES meetings are published, within 12 months
of the first meeting of a specific working group, in a first-line peer-reviewed Journal in the field. Several ad hoc sections have
been constituted, over the years, dealing primarily with musculoskeletal disorders (e.g. Postmenopausal Osteoporosis,
Osteoporosis in men, Glucocorticoid-induced Osteoporosis, Osteoarthritis, Rheumatoid Arthritis, Bone Fracture Healing, ...) but
also with other areas of medicine (e.g. Asthma and Chronic Obstructive Pulmonary Disorders, Hormone Replacement Therapy,
Pharmacogenetics, Ethics, Adherence, Health Economics, Climacteric Symptoms, ...). Whereas the GREES still constitutes an
informal group of interaction between scientists coming from various areas, it is now well accepted, within the scientific
community as one of the most prominent scientific groups, working in perspective of improving patient' well-being.
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Do we need "new points to consider for RA clinical trials?"
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